IDH1 Expression via the R132H Mutation–Specific Antibody in Adrenocortical Neoplasias—Prognostic Impact in Carcinomas | Zendy

Mirkka Pennanen | Zendy; Olli Tynninen | Zendy; Soili Kytölä | Zendy; Pekka Ellonen | Zendy; Harri Mustonen | Zendy; Ilkka Heiskanen | Zendy; Caj Haglund | Zendy; Johanna Arola | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

IDH1 Expression via the R132H Mutation–Specific Antibody in Adrenocortical Neoplasias—Prognostic Impact in Carcinomas

Author(s) -

Mirkka Pennanen,

Olli Tynninen,

Soili Kytölä,

Pekka Ellonen,

Harri Mustonen,

Ilkka Heiskanen,

Caj Haglund,

Johanna Arola

Publication year - 2020

Publication title -

journal of the endocrine society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.046

H-Index - 20

ISSN - 2472-1972

DOI - 10.1210/jendso/bvaa018

Subject(s) - idh1 , immunohistochemistry , adrenocortical carcinoma , isocitrate dehydrogenase , pathology , exon , cancer research , biology , mutation , medicine , gene , genetics , biochemistry , enzyme

Among adrenocortical carcinomas, IDH1 R132H immunopositivity correlated with a better prognosis. Thus, IDH1 R132H immunohistochemical staining could serve as a prognostic or as a potential predictive marker in adrenocortical carcinomas. Further research is needed to identify the possible alterations in IDH1 that could explain our findings, because we identified no known mutations to the gene.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research